(810) Chenodal: payments to doctors
Payments that named (810) Chenodal as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $437K
- Providers
- 269
- Transactions
- 340
- Average per transaction
- $1,286
The per-transaction average — $1,286 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 269 providers the average total is $1,625, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Retrophin, Inc. | $330,813 | 75.7% |
| Travere Therapeutics, Inc. | $54,568 | 12.5% |
| Mirum Pharmaceuticals, Inc. | $51,842 | 11.9% |